Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Dendritic cell-based treatment of cancer: closing in on a cellular therapy.

Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R.

Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61.

PMID:
11777265
2.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
3.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
4.

[Cell therapy and prostate cancer].

Eymard JC, Bernard J.

Bull Cancer. 2003 Aug-Sep;90(8-9):734-43. Review. French.

5.

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S.

Cancer Immunol Immunother. 2006 Dec;55(12):1524-33.

PMID:
16612599
6.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
7.

Dendritic cell-based cancer immunotherapy.

Engleman EG.

Semin Oncol. 2003 Jun;30(3 Suppl 8):23-9. Review.

PMID:
12881809
8.

Clinical experience with CD64-directed immunotherapy. An overview.

Curnow RT.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. Review.

PMID:
9435876
9.

Clinical applications of dendritic cell vaccines.

Morse MA, Lyerly HK.

Curr Opin Mol Ther. 2000 Feb;2(1):20-8. Review.

PMID:
11249649
10.

Technology evaluation: APC-8015, Dendreon.

Rini BI.

Curr Opin Mol Ther. 2002 Feb;4(1):76-9. Review.

PMID:
11883698
11.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
12.

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.

Lin AM, Hershberg RM, Small EJ.

Urol Oncol. 2006 Sep-Oct;24(5):434-41. Review.

PMID:
16962496
13.

Immunotherapy with dendritic cells for cancer.

Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A.

Adv Drug Deliv Rev. 2008 Jan 14;60(2):173-83. Review.

PMID:
17977615
15.

Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.

Büchler T, Hajek R.

Med Oncol. 2002;19(4):213-8. Review.

PMID:
12512914
16.

Advances in specific immunotherapy for prostate cancer.

Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.

Eur Urol. 2008 Apr;53(4):694-708. Review.

PMID:
18061335
17.

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.

J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048.

PMID:
18801509
18.

Recent clinical development of dendritic cell-based immunotherapy for prostate cancer.

Rini B.

Expert Opin Biol Ther. 2004 Nov;4(11):1729-34. Review.

PMID:
15500401
19.
20.

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.

Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-401.

Items per page

Supplemental Content

Support Center